| Name of the Instrument/Tool | Raynaud’s Condition Score (RCS) |
| First Description |
Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998 Apr;41(4):670-7. |
| Year | 1998 |
| Domains | |
| Concept of constructs | Symptom severity, Physical function, Disease activity |
| Population/Disease | Disease specific |
| Originally developed for | Systemic sclerosis, Raynaud's disease |
| Other rheumatic diseases where can be applied (only if validated) |
--- |
| Additional population with no rheumatic diseases |
No |
| Language: Originally published in | English |
| Available in Language | English, French |
| REFERENCE IDENTIFICATION | |
| Author/s | Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR. |
| Title | Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. |
| Journal | Arthritis Rheum |
| Year | 1998 |
| Vol | 41 |
| Num | 4 |
| Pages | 670-7 |
| Country | USA |
| Language | English |
| Other references of interest | |
| Link | http://www.ncbi.nlm.nih.gov/pubmed/12355489 |
| Brief Description |
Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM; Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 2002 Sep;46(9):2410-20. |
| Link | http://www.ncbi.nlm.nih.gov/pubmed/19364728 |
| Brief Description |
Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis. 2010 Mar;69(3):588-91. |
| Link | https://pubmed.ncbi.nlm.nih.gov/33091259/ |
| Brief Description |
An update on outcome measures in Systemic Sclerosis |
| Instrument/Tool Translations References | |
| No other References. | |
| DEVELOPER CONTACT INFORMATION | |
| Correspondence to | Peter Merkel |
| pmerkel@bu.edu | |
| Address | Sections of Rheumatology and Clinical Epidemiology Research and Training, Arthritis Center, Evans 5, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118 |
| Website | --- |
| Available | --- |
| Links | --- |
| DESCRIPTION OF THE INSTRUMENT | |
| Type Of Measure | Scale |
| Brief Description |
The RCS is a daily self-assessment of RP activity taken over 1 or 2-week period that assesses the daily frequency, duration, severity, and overall impact of RP attacks. It is administered either as a visual analog scale (VAS, 0–100) or on an 11-point Likert scale. |
| Number of Items | 1 |
| Range | 0-10 or 0-100 |
| Responses options/scale |
Yes VAS 0-10 or 0-100 |
| Developed for | Research |
| PRACTICAL APPLICATION | |
| Method of administration | Self-administered |
| Recommendations to score |
The number on the ordinal scale completed daily is added and divided by the number of days it has been completed to get a mean RCS for a period of time. |
| Score Interpretation | Higher score is worse |
| Cut-off points | --- |
| Cut-off points applied to | --- |
| Smallest detectable change if described | --- |
| Smallest detectable change applied to | --- |
| Completion time by the patient | - minutes |
| Scoring time by the assessor | - minutes |
| Training to score | Not necessary |
| Strengths | Useful in clinical practice & research |
| Limitations | --- |
| OTHER COMMENTS | |
| Other Comments | --- |